Please assess the completion status of the following clinical trial:

Trial Title: Ketamine in Chronic Kid's (KiCK) Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subject, parent, or guardian willing and able to give informed consent~* NRS for pain over the past 24 hours \>4 at baseline~* Chronic pain, which has been present for \>3 months, or persisting longer than is normal for the underlying diagnosis~* Chronic pain related to physiologic diagnoses including but not limited to: cancer, rheumatologic disease, sickle cell anemia, cystic fibrosis, pancreatitis, and neuromuscular disease (e.g. Duchenne muscular dystrophy)~* Able to tolerate and cooperate with neurocognitive assessment~* Age 8-20 years old~Exclusion Criteria:~* If they are known or suspected to have drug addiction~* Uncontrolled psychiatric disorder such as depression, schizophrenia, or bipolar disorder~* Uncontrolled hypertension~* Known liver disease or elevation of AST or ALT greater than 3 times the upper limit of normal.~* Previous intolerance or allergic reaction to ketamine~* Pregnancy~* Use of CYP3A4 inhibitors or inducers within the 2-week period prior the study drug administration or within 5 half-lives of the respective medication, whichever is longer, until study conclusion.~* Consumption of grapefruit or grapefruit products from at least 2 weeks prior to study drug administration until study conclusion.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine 0.25 mg/kg/dose (Type: EXPERIMENTAL): A 5mL solution of 0.25 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
- Ketamine 0.5 mg/kg/dose (Type: EXPERIMENTAL): A 5mL solution of 0.5 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
- Ketamine 1 mg/kg/dose (Type: EXPERIMENTAL): A 5mL solution of 1 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).